ClinicalTrials.gov posted results on 4 September 2026 for a completed Phase 3 study of orforglipron in adults with obesity or overweight and type 2 diabetes. Among 1,613 participants, least-squares mean body-weight changes ranged from −5.50% with 6 mg once daily to −10.54% with 36 mg once daily, compared with −2.21% for placebo.

Background

The trial evaluated once-daily oral orforglipron against placebo for body-weight change in adults with obesity or overweight and type 2 diabetes. The study summary described an approximately 77-week trial with up to 22 visits. The registry listed obesity, overweight, and type 2 diabetes as the study conditions.

Trial design

This was a Phase 3 study identified as NCT05872620 and listed as completed. It enrolled 1,613 participants and compared orforglipron doses of 6 mg, 12 mg, and 36 mg once daily with placebo. The supplied record did not include primary-outcome entries, although it reported body-weight and responder measurements.

Key results

The reported least-squares mean percentage changes from baseline in body weight were:

  • Placebo: −2.21%, standard error 0.215.
  • 6 mg orforglipron once daily: −5.50%, standard error 0.356.
  • 12 mg orforglipron once daily: −7.78%, standard error 0.411.
  • 36 mg orforglipron once daily: −10.54%, standard error 0.466.

The percentages achieving at least 5% weight reduction were 24.4% with placebo, 49.8% with 6 mg, 60.2% with 12 mg, and 72.8% with 36 mg. For at least 10% reduction, the corresponding figures were 7.0%, 23.9%, 35.5%, and 50.1%.

Mixed-model analyses reported net least-squares mean differences of −3.28 (95% CI, −4.10 to −2.47), −5.56 (95% CI, −6.48 to −4.65), and −8.33 (95% CI, −9.34 to −7.32), each with p=0.001. Logistic regression risk differences were 25.43 (95% CI, 18.54 to 32.31), 35.79 (95% CI, 29.12 to 42.45), and 48.37 (95% CI, 41.95 to 54.80), also each with p=0.001.

What this means

The posted measurements showed greater average weight loss and higher proportions reaching 5% and 10% weight-reduction thresholds with each orforglipron dose than with placebo. The results also showed a dose-related pattern across the three once-daily doses. The supplied record did not include an adverse-event summary, so these data do not describe comparative safety.

Source

Source: ClinicalTrials.gov, registry results for “A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes,” NCT05872620, posted 4 September 2026. Available at clinicaltrials.gov/study/NCT05872620.